Innoviva (INVA) concentration risks

The company's disclosed concentration profile is defined by a single dominant counterparty and two specific products tied to that relationship. The company derives the majority of its revenues from GSK, and the filing explicitly states that near-term success depends in large part on GSK — a moderate-share customer concentration with a dependency character. This is not a transient customer mix issue but a structural feature of the business model: the company is a royalty-generating entity whose cash flows are governed by the commercial performance of licensed products sold by its principal partner. Layered directly on top of the customer concentration is a product exposure: royalty revenues from RELVAR/BREO ELLIPTA and ANORO ELLIPTA are expected to represent the majority of foreseeable future revenues from GSK. This is also a moderate-share exposure with a mixed character — structural in that these are established respiratory products with existing prescriber bases, and idiosyncratic in that the royalty stream is sensitive to competitive pressures in the inhaled corticosteroid and long-acting bronchodilator markets, pricing dynamics, and any changes to the contractual royalty terms. Because both exposures are moderate by disclosed size and tied to the same counterparty and the same product categories, they compound rather than diversify each other. A decline in the commercial trajectory of those two respiratory products at GSK would flow through directly to the company's revenue line. GSK's commercial execution and the durability of those franchises are therefore the primary variables to monitor.

For the engine’s reasoning on INVA’s current verdict — including which dimensions drove the score — see the per-dimension breakdown.

Concentration counts reflect items disclosed in each peer’s most recent 10-K; disclosed-size classification uses TrendMatrix’s internal 10-K extraction taxonomy.